Investment Rating - The report does not explicitly state an investment rating for the industry [19]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 5.61% from April 7 to April 11, underperforming compared to the Wind All A index (-4.31%) and the CSI 300 index (-2.87%) [2][7]. - Blood products (4.06%) and offline pharmacies (1.81%) were the leading sub-sectors, while medical research outsourcing (-16.04%), in vitro diagnostics (-8.28%), and pharmaceutical distribution (-6.4%) faced the largest declines [2][8]. - Recent policies in Beijing and Shenzhen aim to support the innovation of drugs and medical devices, enhancing clinical research efficiency and accelerating the approval process for innovative products [2][11]. - The FDA announced a shift towards non-clinical evaluation methods, moving away from animal testing for monoclonal antibodies and other drugs, promoting the use of AI-based toxicity models and organoid testing [2][12]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector saw a weekly decline of 5.61%, with blood products and offline pharmacies showing positive growth [7]. - The top three gainers were Yirui Technology (20.5%), Yipinhong (17.0%), and Yong'an Pharmaceutical (13.9%), while the largest decliners included Rundu Co., Ltd. (-27.8%), Duorui Pharmaceutical (-27.2%), and Boteng Co., Ltd. (-22.2%) [10]. Industry News and Key Company Announcements Important Industry Events - The report highlights significant policy changes aimed at fostering the development of innovative drugs and medical devices in major cities [11][12]. - The approval of a gene therapy for hemophilia B by Xinnian Pharmaceutical marks a milestone as the first domestic gene therapy for this condition [11][13]. Company Announcements - ADC company Ying'en Bio completed its IPO, raising over $200 million [15]. - Hongchang Bio presented promising results for its innovative drug Telitacicept at a neurology conference, showing significant improvement in myasthenia gravis patients [15]. - Heng Rui Pharmaceutical announced a licensing agreement with Merck KGaA for its GnRH receptor antagonist, SHR7280, with an upfront payment of €15 million [15][16].